SG10201510406YA - Long - acting formulations of insulins - Google Patents

Long - acting formulations of insulins

Info

Publication number: SG10201510406YA
Authority: SG; Singapore
Prior art keywords: insulins; long; acting formulations; formulations; acting
Prior art date: 2010-05-19

Application number

SG10201510406YA

Inventor

Reinhard Becker

Annke Frick

Peter Boderke

Christiane Fuerst

Werner Mueller

Katrin Tertsch

Ulrich Werner

Petra Loos

Isabell Schoettle

Original Assignee

Sanofi Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-05-19

Filing date

2011-05-18

Publication date

2016-01-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44148980&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201510406Y(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-05-18 Application filed by Sanofi Sa filed Critical Sanofi Sa

2016-01-28 Publication of SG10201510406YA publication Critical patent/SG10201510406YA/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oil, Petroleum & Natural Gas (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Inorganic Chemistry (AREA)
Dermatology (AREA)
Vascular Medicine (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Hematology (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Peptides Or Proteins (AREA)

SG10201510406YA 2010-05-19 2011-05-18 Long - acting formulations of insulins SG10201510406YA (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP10305532		2010-05-19
EP10305780		2010-07-13
EP11305140		2011-02-10

Publications (1)

Publication Number	Publication Date
SG10201510406YA true SG10201510406YA (en)	2016-01-28

Family

ID=44148980

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SG10201510406YA SG10201510406YA (en)	2010-05-19	2011-05-18	Long - acting formulations of insulins
SG2012084208A SG185593A1 (en)	2010-05-19	2011-05-18	Long - acting formulations of insulins

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
SG2012084208A SG185593A1 (en)	2010-05-19	2011-05-18	Long - acting formulations of insulins

Country Status (44)

Country	Link
US (11)	US20110301081A1 (en)
EP (9)	EP3424491A1 (en)
JP (5)	JP5269945B2 (en)
KR (4)	KR101989343B1 (en)
CN (5)	CN107583038A (en)
AR (1)	AR081200A1 (en)
AU (1)	AU2011202239C1 (en)
BR (2)	BR112012029131B1 (en)
CA (1)	CA2792669C (en)
CL (1)	CL2012003197A1 (en)
CO (1)	CO6640217A2 (en)
CR (1)	CR20120578A (en)
CY (3)	CY1115649T1 (en)
DK (3)	DK2781212T3 (en)
DO (1)	DOP2012000261A (en)
EC (1)	ECSP12012298A (en)
ES (4)	ES2509943T3 (en)
FI (1)	FI2571517T4 (en)
GT (1)	GT201200287A (en)
HK (4)	HK1248593A1 (en)
HR (3)	HRP20181028T2 (en)
HU (2)	HUE039355T2 (en)
IL (2)	IL221964A (en)
JO (2)	JO2944B1 (en)
LT (2)	LT2781212T (en)
MA (1)	MA34224B1 (en)
MX (2)	MX343489B (en)
MY (1)	MY156188A (en)
NI (1)	NI201200152A (en)
NZ (1)	NZ602541A (en)
PE (2)	PE20130511A1 (en)
PH (3)	PH12012501895A1 (en)
PL (4)	PL3824876T3 (en)
PT (3)	PT2387989E (en)
RS (1)	RS53559B1 (en)
RU (3)	RU2564104C2 (en)
SG (2)	SG10201510406YA (en)
SI (3)	SI2781212T1 (en)
TN (1)	TN2012000478A1 (en)
TR (2)	TR201809475T4 (en)
TW (4)	TWI469787B (en)
UY (1)	UY33391A (en)
WO (1)	WO2011144673A2 (en)
ZA (1)	ZA201206998B (en)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK1969004T3 (en)	2005-12-28	2011-11-28	Novo Nordisk As	Insulin compositions and method of making a composition
MY152979A (en)	2008-01-09	2014-12-15	Sanofi Aventis Deutschland	Novel insulin derivatives having an extremely delayed time-action profile
PL3228320T3 (en)	2008-10-17	2020-06-01	Sanofi-Aventis Deutschland Gmbh	Combination of an insulin and a glp-1 agonist
ES2607003T3 (en)	2008-10-30	2017-03-28	Novo Nordisk A/S	Treatment of diabetes mellitus using insulin injections with an injection frequency less than daily
JO3672B1 (en)	2008-12-15	2020-08-27	Regeneron Pharma	High Affinity Human Antibodies to PCSK9
TWI520745B (en) *	2009-07-06	2016-02-11	賽諾菲阿凡提斯德意志有限公司	Insulin preparation containing methionine
SI2498801T1 (en)	2009-11-13	2018-06-29	Sanofi-Aventis Deutschland Gmbh	PHARMACEUTICAL COMPOSITION COMPRISING desPro36Exendin-4(1-39)-Lys6-NH2 AND METHIONINE
CA3011480C (en)	2009-11-13	2021-11-09	Sanofi-Aventis Deutschland Gmbh	Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
AU2011202239C1 (en)	2010-05-19	2017-03-16	Sanofi	Long-acting formulations of insulins
EP2611458B1 (en)	2010-08-30	2016-09-21	Sanofi-Aventis Deutschland GmbH	Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
JP6049625B2 (en)	2010-10-27	2016-12-21	ノヴォノルディスクアー／エス	Treatment of diabetes mellitus using insulin injections given at various injection intervals
AR084938A1 (en)	2011-01-28	2013-07-10	Sanofi Sa	HUMAN ANTIBODIES AGAINST PROPROTEIN CONVERTASA SUBTILISINA / KEXINA TYPE 9 (ANTI PCSK9) FOR USE IN METHODS TO TREAT PATIENT GROUPS
US9821032B2 (en)	2011-05-13	2017-11-21	Sanofi-Aventis Deutschland Gmbh	Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
AR087305A1 (en)	2011-07-28	2014-03-12	Regeneron Pharma	STABILIZED FORMULATIONS CONTAINING ANTI-PCSK9 ANTIBODIES, PREPARATION METHOD AND KIT
FR2984749A1 (en) *	2011-12-23	2013-06-28	Adocia	Composition, useful for treating diabetes, comprises basal insulin, and a dextran substituted by carboxylate charge carrier radicals and hydrophobic radicals
BR112014002986A2 (en)	2011-08-10	2017-06-13	Adocia	composition in the form of a solution for injection, and single dose formulation
EP2750699B1 (en)	2011-08-29	2015-07-22	Sanofi-Aventis Deutschland GmbH	Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
TWI559929B (en)	2011-09-01	2016-12-01	Sanofi Aventis Deutschland	Pharmaceutical composition for use in the treatment of a neurodegenerative disease
TW201333870A (en) *	2011-12-21	2013-08-16	艾登工具股份有限公司	Systems and methods for determining insulin therapy for a patient
FR2985429B1 (en) *	2012-01-09	2016-07-29	Adocia	PH 7 INJECTABLE SOLUTION COMPRISING AT LEAST ONE BASIC INSULIN WITH A PI BETWEEN 5.8 AND 8.5 AND A SUBSTITUTED POLYAMINOACID OBTAINED BY A CONTROLLED POLYMERIZATION PROCESS
FR2985428B1 (en) *	2012-01-09	2016-05-27	Adocia	PH 7 INJECTABLE SOLUTION COMPRISING AT LEAST ONE BASIC INSULIN WITH A PI BETWEEN 5.8 AND 8.5 AND A SUBSTITUTED POLYAMINOACIDE
WO2013104861A1 (en) *	2012-01-09	2013-07-18	Adocia	Injectable solution having a ph of 7 and including at least basal insulin, the pi of which is between 5.8 and 8.5, and a substituted co-poly(amino acid)
US9588130B2 (en)	2012-04-18	2017-03-07	Waters Technologies Corporation	Methods for quantifying polypeptides using mass spectrometry
AR092862A1 (en) *	2012-07-25	2015-05-06	Hanmi Pharm Ind Co Ltd	LIQUID FORMULATION OF PROLONGED ACTION INSULIN AND AN INSULINOTROPIC PEPTIDE AND PREPARATION METHOD
US20150314003A2 (en)	2012-08-09	2015-11-05	Adocia	Injectable solution at ph 7 comprising at least one basal insulin the isoelectric point of which is between 5.8 and 8.5 and a hydrophobized anionic polymer
FR3001896B1 (en)	2013-02-12	2015-07-03	Adocia	PH 7 INJECTABLE SOLUTION COMPRISING AT LEAST ONE BASIC INSULIN WHERE THE ISO-ELECTRIC POINT IS BETWEEN 5.8 AND 8.5 AND A HYDROPHOBIC ANIONIC POLYMER
UA116217C2 (en)	2012-10-09	2018-02-26	Санофі	Exendin-4 derivatives as dual glp1/glucagon agonists
FR3001895B1 (en)	2013-02-12	2015-07-03	Adocia	PH7 INJECTABLE SOLUTION COMPRISING AT LEAST ONE BASIC INSULIN WHERE THE ISOELECTRIC POINT IS INCLUDED IN 5.8 AND 8.5 AND AN ANIONIC COMPOUND CARRYING CARBOXYLATE LOADS AND HYDROPHOBIC RADICALS
AU2013365945B2 (en) *	2012-12-19	2017-03-02	Wockhardt Limited	A stable aqueous composition comprising human insulin or an analogue or derivative thereof
CA2895875A1 (en)	2012-12-21	2014-06-26	Sanofi	Exendin-4 derivatives
CN103893744B (en) *	2012-12-24	2017-12-19	杭州九源基因工程有限公司	A kind of pharmaceutical preparation for treating diabetes and preparation method thereof
NZ707168A (en) *	2012-12-26	2016-09-30	Wockhardt Ltd	Pharmaceutical composition of insulins
TWI780236B (en)	2013-02-04	2022-10-11	法商賽諾菲公司	Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
WO2014147141A1 (en) *	2013-03-20	2014-09-25	Novo Nordisk A/S	Insulin dosing regimen
US20220202711A1 (en) *	2013-04-03	2022-06-30	Sanofi	Treatment of Diabetes Mellitus by Long-Acting Formulations of Insulins
EP4613284A3 (en) *	2013-04-03	2025-11-19	Sanofi	Treatment of diabetes mellitus by long-acting formulations of insulins
WO2014177623A1 (en)	2013-04-30	2014-11-06	Novo Nordisk A/S	Novel administration regime
EP3010530B1 (en) *	2013-06-17	2018-12-26	Sanofi-Aventis Deutschland GmbH	Insulin glargine/lixisenatide fixed ratio formulation
CN104587455A (en) *	2013-10-31	2015-05-06	江苏万邦生化医药股份有限公司	Insulin preparation
EP3080150B1 (en)	2013-12-13	2018-08-01	Sanofi	Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
WO2015086730A1 (en)	2013-12-13	2015-06-18	Sanofi	Non-acylated exendin-4 peptide analogues
EP3080154B1 (en)	2013-12-13	2018-02-07	Sanofi	Dual glp-1/gip receptor agonists
WO2015086733A1 (en)	2013-12-13	2015-06-18	Sanofi	Dual glp-1/glucagon receptor agonists
WO2015086731A1 (en)	2013-12-13	2015-06-18	Sanofi	Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonists
RU2016132342A (en)	2014-01-09	2018-02-14	Санофи	STABILIZED PHARMACEUTICAL COMPOSITIONS BASED ON INSULIN ANALOGUES AND / OR INSULIN DERIVATIVES
CN105899191B (en)	2014-01-09	2020-06-16	赛诺菲	Stabilized glycerol-free pharmaceutical preparations of insulin analogs and/or insulin derivatives
RU2016132340A (en)	2014-01-09	2018-02-14	Санофи	STABILIZED PHARMACEUTICAL COMPOSITIONS BASED ON INSULIN ASPART
CN103830189A (en) *	2014-03-04	2014-06-04	山东新时代药业有限公司	Recombinant insulin glargine preparation and preparation method thereof
AU2015239020A1 (en)	2014-04-04	2016-10-13	Sanofi	Substituted indanone compounds as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
TW201623286A (en)	2014-04-04	2016-07-01	賽諾菲公司	Isoindolinone compounds as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
AR099936A1 (en)	2014-04-04	2016-08-31	Sanofi Sa	CONDENSED HETEROCICLES REPLACED AS MODULATORS OF GPR119 FOR THE TREATMENT OF DIABETES, OBESITY, DISLIPIDEMIA AND RELATED DISORDERS
TW201625669A (en)	2014-04-07	2016-07-16	賽諾菲公司	Peptidic dual GLP-1/glucagon receptor agonists derived from Exendin-4
TW201625670A (en)	2014-04-07	2016-07-16	賽諾菲公司	Dual GLP-1/glucagon receptor agonists derived from EXENDIN-4
TW201625668A (en)	2014-04-07	2016-07-16	賽諾菲公司	Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists
US9932381B2 (en)	2014-06-18	2018-04-03	Sanofi	Exendin-4 derivatives as selective glucagon receptor agonists
WO2016001862A1 (en)	2014-07-04	2016-01-07	Wockhardt Limited	Extended release formulations of insulins
KR20240017117A (en)	2014-07-16	2024-02-06	사노피 바이오테크놀로지	METHODS FOR TREATING PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA(heFH)
PE20171622A1 (en) *	2014-12-12	2017-11-02	Sanofi Aventis Deutschland	INSULIN GLARGIN / LIXISENATIDE FIXED RATIO FORMULATION
CN104688677B (en) *	2015-02-05	2018-02-09	通化东宝药业股份有限公司	A kind of insulin glargine injecta of stabilization and preparation method thereof
CN104688678B (en) *	2015-02-05	2017-11-17	通化东宝药业股份有限公司	A kind of preparation method of insulin glargine injecta and its insulin glargine injecta of preparation
TWI748945B (en)	2015-03-13	2021-12-11	德商賽諾菲阿凡提斯德意志有限公司	Treatment type 2 diabetes mellitus patients
TW201705975A (en)	2015-03-18	2017-02-16	賽諾菲阿凡提斯德意志有限公司	Treatment of type 2 diabetes mellitus patients
AR105319A1 (en)	2015-06-05	2017-09-27	Sanofi Sa	PROPHARMS THAT INCLUDE A DUAL AGONIST GLU-1 / GLUCAGON CONJUGATE HIALURONIC ACID CONNECTOR
WO2016198628A1 (en)	2015-06-12	2016-12-15	Sanofi	Non-acylated exendin-4 derivatives as dual glp-1/glucagon receptor agonists
WO2016198624A1 (en)	2015-06-12	2016-12-15	Sanofi	Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
AR105284A1 (en)	2015-07-10	2017-09-20	Sanofi Sa	DERIVATIVES OF EXENDINA-4 AS SPECIFIC DUAL PEPTIDE AGONISTS OF GLP-1 / GLUCAGÓN RECEPTORS
EA201890519A1 (en)	2015-08-18	2018-07-31	Ридженерон Фармасьютикалз, Инк.	INHIBITING ANTIBODIES AGAINST PCSK9 FOR THE TREATMENT OF PATIENTS WITH HYPERLIPIDEMIA EXPOSING TO LIPOPROTEIN SCARVA
EA039114B1 (en) *	2015-11-10	2021-12-06	Санофи-Авентис Дойчланд Гмбх	Use of insulin glargine/lixisenatide fixed ratio composition in the treatment of diabetes mellitus type 2
TW201731867A (en)	2015-12-02	2017-09-16	賽諾菲公司	FGF21 variant
CN105597087B (en) *	2016-01-06	2019-04-26	山东新时代药业有限公司	A kind of insulin glargine injecta and preparation method thereof
GB201607918D0 (en)	2016-05-06	2016-06-22	Arecor Ltd	Novel formulations
WO2018055539A1 (en)	2016-09-22	2018-03-29	Wockhardt Limited	Pharmaceutical composition containing buffered insulin glargine and glp-1 analogue
AR110300A1 (en)	2016-12-02	2019-03-13	Sanofi Sa	COMPOUNDS AS TRIGONAL PEPTIDE AGONISTS OF GLP1 / GLUCAGÓN / GIP RECEPTORS
AR110301A1 (en)	2016-12-02	2019-03-13	Sanofi Sa	COMPOUNDS AS GLP1 / GLUCAGÓN / GIP RECEPTING AGENISTS
TW201832783A (en)	2016-12-02	2018-09-16	法商賽諾菲公司	Conjugates comprising an glp-1/glucagon dual agonist, a linker and hyaluronic acid
CN110087671A (en)	2016-12-22	2019-08-02	赛诺菲	FGF21 compound/GLP-1R agonist combinations with optimized activity ratios
US20190031774A1 (en)	2017-06-09	2019-01-31	Sanofi Biotechnology	Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitor
AU2018308692A1 (en) *	2017-07-27	2020-03-05	Adocia	Compositions in the form of an injectable aqueous solution comprising at least human insulin A21G and a prandial action glucagon suppressor
TW202015735A (en)	2018-05-30	2020-05-01	法商賽諾菲公司	Conjugates comprising an glp-1/glucagon/gip triple receptor agonist, a linker and hyaluronic acid
JP2021528422A (en)	2018-06-21	2021-10-21	サノフイＳａｎｏｆｉ	Combination of FGF21 compound / GLP-1R agonist with optimized activity ratio
WO2019243628A1 (en)	2018-06-22	2019-12-26	Adocia	Injectable composition with a ph of 7 comprising a co-polyaminoacid bearing carboxylate charges and hydrophobic radicals and at least one basal insulin having at least a prandial effect and a basal effect
US10335464B1 (en)	2018-06-26	2019-07-02	Novo Nordisk A/S	Device for titrating basal insulin
US20220233784A1 (en)	2019-05-29	2022-07-28	Sanofi	Drug delivery device
WO2021009027A1 (en)	2019-07-12	2021-01-21	Novo Nordisk A/S	High concentration insulin formulation
FI4069278T3 (en) *	2019-12-06	2025-07-16	Dr Mary Morris & Ass Llc	Methods and compositions for the prevention of type 1 diabetes
KR20210144609A (en) *	2020-05-22	2021-11-30	한미약품 주식회사	A liquid formulation of a long-acting conjugate of trigonal glucagon/GLP-1/GIP receptor agonist
KR20230034356A (en)	2020-07-02	2023-03-09	사노피	GLP-1R agonist peptides with reduced activity
JP2023540663A (en)	2020-07-02	2023-09-26	サノフイ	GLP-1R agonist/FGF21 fusion protein
US20230302095A1 (en) *	2020-08-14	2023-09-28	Kyon Biotech Ag	Increasing the efficacy of biological therapeutic molecules
AU2021356578A1 (en) *	2020-10-08	2023-05-11	Dr. Mary Morris & Associates, Llc	Methods and compositions for the treatment and prevention of type 1 diabetes

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4960702A (en)	1985-09-06	1990-10-02	Codon	Methods for recovery of tissue plasminogen activator
PH23446A (en)	1986-10-20	1989-08-07	Novo Industri As	Peptide preparations
DE3837825A1 (en) *	1988-11-08	1990-05-10	Hoechst Ag	NEW INSULIN DERIVATIVES, THEIR USE AND A PHARMACEUTICAL PREPARATION CONTAINING THEM
CH682806A5 (en) *	1992-02-21	1993-11-30	Medimpex Ets	Injection device.
CH682805A5 (en) *	1992-02-24	1993-11-30	Medimpex Ets	Display device for an injection device.
CZ295827B6 (en)	1994-03-07	2005-11-16	Nektar Therapeutics	Method for aerosolizing a dose of insulin, insulin composition and use thereof
AR002976A1 (en) *	1995-03-31	1998-05-27	Lilly Co Eli	PARENTERAL PHARMACEUTICAL FORMULATIONS OF LONG-TERM EFFECT OF INSULIN; CRYSTALS OF SUCH ANALOGUES APPLICABLE IN SUCH FORMULATIONS AND PROCEDURE OF THE FORMULATIONS MENTIONED
CO4750643A1 (en)	1997-06-13	1999-03-31	Lilly Co Eli	STABLE FORMULATION OF INSULIN CONTAINING L-ARGININ AND PROTAMINE
CA2306905A1 (en)	1997-10-24	1999-05-06	Eli Lilly And Company	Fatty acid-acylated insulin analogs
US6978471B1 (en)	1999-05-25	2005-12-20	Thomson Licensing S.A.	System for acquiring and processing broadcast programs and program guide data
US6528486B1 (en)	1999-07-12	2003-03-04	Zealand Pharma A/S	Peptide agonists of GLP-1 activity
EP1076066A1 (en)	1999-07-12	2001-02-14	Zealand Pharmaceuticals A/S	Peptides for lowering blood glucose levels
US7022674B2 (en)	1999-12-16	2006-04-04	Eli Lilly And Company	Polypeptide compositions with improved stability
DK1326630T3 (en)	2000-09-18	2008-09-15	Sanos Bioscience As	Use of GLP-2 peptides
WO2002067969A2 (en)	2001-02-21	2002-09-06	Medtronic Minimed, Inc.	Stabilized insulin formulations
US20030026872A1 (en)	2001-05-11	2003-02-06	The Procter & Gamble Co.	Compositions having enhanced aqueous solubility and methods of their preparation
FR2827604B1 (en)	2001-07-17	2003-09-19	Sanofi Synthelabo	NOVEL 1-PHENYLSULFONYL-1,3-DIHYDRO-2H-INDOL-2- ONE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
WO2003020201A2 (en) *	2001-08-28	2003-03-13	Eli Lilly And Company	Pre-mixes of glp-1 and basal insulin
US20100069293A1 (en)	2002-02-27	2010-03-18	Pharmain Corporation	Polymeric carrier compositions for delivery of active agents, methods of making and using the same
US7115563B2 (en)	2002-05-29	2006-10-03	Insignion Holding Limited	Composition and its therapeutic use
DE10227232A1 (en)	2002-06-18	2004-01-15	Aventis Pharma Deutschland Gmbh	Sour insulin preparations with improved stability
ES2327328T3 (en)	2002-07-04	2009-10-28	Zealand Pharma A/S	GLP-1 AND PROCEDURES FOR THE TREATMENT OF DIABETES.
DE10235168A1 (en)	2002-08-01	2004-02-12	Aventis Pharma Deutschland Gmbh	Process for the purification of preproinsulin
GB0309154D0 (en)	2003-01-14	2003-05-28	Aventis Pharma Inc	Use of insulin glargine to reduce or prevent cardiovascular events in patients being treated for dysglycemia
CA2498224C (en)	2003-01-21	2011-03-22	Ortho-Tain Inc.	A dental appliance and a system and a method for reducing an amount of patient cooperation to treat a malocclusion using the dental appliance
GB0304822D0 (en) *	2003-03-03	2003-04-09	Dca Internat Ltd	Improvements in and relating to a pen-type injector
DE602004029630D1 (en)	2003-03-04	2010-12-02	Technology Dev Co Ltd	Injectable long-acting insulin preparation and process for its preparation and use
CA2542372A1 (en)	2003-08-29	2005-03-10	Centocor, Inc.	Method of promoting graft survival with anti-tissue factor antibodies
EP1699629B1 (en) *	2003-12-22	2010-10-06	Novo Nordisk A/S	Transparent, flexible , impermeable plastic container for storage of pharmaceutical liquids
US7192919B2 (en)	2004-01-07	2007-03-20	Stelios Tzannis	Sustained release compositions for delivery of pharmaceutical proteins
US20080248999A1 (en)	2007-04-04	2008-10-09	Biodel Inc.	Amylin formulations
KR20070004078A (en)	2004-03-31	2007-01-05	센토코 인코포레이티드	Human JLP-1 mimetics, compositions, methods and uses
SG158158A1 (en)	2004-12-22	2010-01-29	Centocor Inc	Glp-1 agonists, compositions, methods and uses
US7879361B2 (en)	2005-01-04	2011-02-01	Gp Medical, Inc.	Nanoparticles for drug delivery
EP1945142B1 (en)	2005-09-26	2013-12-25	Medtronic, Inc.	Prosthetic cardiac and venous valves
US8084420B2 (en)	2005-09-29	2011-12-27	Biodel Inc.	Rapid acting and long acting insulin combination formulations
US8530447B2 (en) *	2005-10-24	2013-09-10	Nestec S.A.	Dietary fiber formulation and method of administration
CN101309668A (en)	2005-11-30	2008-11-19	健乐克斯医药公司	Orally absorbed pharmaceutical preparations and methods of administration
US20100029558A1 (en)	2005-12-06	2010-02-04	Bristow Cynthia L	Alpha1 proteinase inhibitor peptides methods and use
CN101454019A (en) *	2006-04-12	2009-06-10	百达尔公司	Rapid acting and long acting insulin combination formulations
JP2009539778A (en)	2006-06-08	2009-11-19	ダイアベコアメディカルインコーポレイテッド	Insulin oligomer derivative
DE102006031962A1 (en) *	2006-07-11	2008-01-17	Sanofi-Aventis Deutschland Gmbh	Amidated insulin glargine
JP2009544716A (en) *	2006-07-27	2009-12-17	ノバルティスアクチエンゲゼルシャフト	Insulin-containing aerosolizable formulation for pulmonary delivery
AU2008287063B2 (en)	2007-08-09	2013-10-24	Genzyme Corporation	Method of treating autoimmune disease with mesenchymal stem cells
WO2009021955A1 (en)	2007-08-13	2009-02-19	Novo Nordisk A/S	Rapid acting insulin analogues
US8937042B2 (en)	2007-11-16	2015-01-20	Novo Nordisk A/S	Pharmaceutical compositions comprising GLP-1 peptides or extendin-4 and a basal insulin peptide
EP2234644B1 (en)	2008-01-04	2013-07-31	Biodel, Inc.	Insulin formulations for insulin release as a function of tissue glucose levels
MY161892A (en)	2008-02-19	2017-05-15	Biocon Ltd	A method of obtaining a purified, biologically active heterologous protein
US8329419B2 (en)	2008-05-23	2012-12-11	Amylin Pharmaceuticals, Llc	GLP-1 receptor agonist bioassays
TWI451876B (en)	2008-06-13	2014-09-11	Lilly Co Eli	Pegylated insulin lispro compounds
WO2010028055A1 (en)	2008-09-02	2010-03-11	Biodel, Inc.	Insulin with a basal release profile
DE102008053048A1 (en) *	2008-10-24	2010-04-29	Sanofi-Aventis Deutschland Gmbh	Medicament, useful e.g. for treating diabetes, controlling fasting, postprandial or postabsorptive blood glucose concentration in diabetic patients and improving glucose tolerance, comprises insulin and glucagon-like peptide-1 agonist
PL3228320T3 (en)	2008-10-17	2020-06-01	Sanofi-Aventis Deutschland Gmbh	Combination of an insulin and a glp-1 agonist
ES2607003T3 (en)	2008-10-30	2017-03-28	Novo Nordisk A/S	Treatment of diabetes mellitus using insulin injections with an injection frequency less than daily
NZ594044A (en)	2009-02-13	2014-08-29	Boehringer Ingelheim Int	Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
US8709400B2 (en)	2009-07-27	2014-04-29	Washington University	Inducement of organogenetic tolerance for pancreatic xenotransplant
NZ597964A (en) *	2009-07-31	2014-04-30	Sanofi Aventis Deutschland	Long acting insulin composition
CA3011480C (en)	2009-11-13	2021-11-09	Sanofi-Aventis Deutschland Gmbh	Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
ES2398012T5 (en)	2009-11-13	2020-02-26	Sanofi Aventis Deutschland	Lixisenatide as complementary therapy to insulin glargine and metformin to treat type 2 diabetes
US20110118178A1 (en)	2009-11-13	2011-05-19	Sanofi-Aventis Deutschland Gmbh	Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin
US20110118180A1 (en)	2009-11-13	2011-05-19	Sanofi-Aventis Deutschland Gmbh	Method of treatment of diabetes type 2 comprising add-on therapy to metformin
SI2498801T1 (en)	2009-11-13	2018-06-29	Sanofi-Aventis Deutschland Gmbh	PHARMACEUTICAL COMPOSITION COMPRISING desPro36Exendin-4(1-39)-Lys6-NH2 AND METHIONINE
WO2011075623A1 (en)	2009-12-18	2011-06-23	Latitude Pharmaceuticals, Inc.	One - phase gel compos ition compri s ing phos pholi pids
CA2790495A1 (en)	2010-02-22	2011-08-25	Case Western Reserve University	Long-acting insulin analogue preparations in soluble and crystalline forms
AR081066A1 (en)	2010-04-02	2012-06-06	Hanmi Holdings Co Ltd	INSULIN CONJUGATE WHERE AN IMMUNOGLOBULIN FRAGMENT IS USED
UY33326A (en)	2010-04-14	2011-12-01	Sanofi Aventis	INSULIN-SIRNA CONJUGATES
US8637458B2 (en)	2010-05-12	2014-01-28	Biodel Inc.	Insulin with a stable basal release profile
AU2011202239C1 (en)	2010-05-19	2017-03-16	Sanofi	Long-acting formulations of insulins
WO2011144674A2 (en)	2010-05-20	2011-11-24	Sanofi-Aventis Deutschland Gmbh	PHARMACEUTICAL FORMULATION COMPRISING INSULIN GLARGINE AND SBE4-ß-CYD
EP2389945A1 (en)	2010-05-28	2011-11-30	Sanofi-Aventis Deutschland GmbH	Pharmaceutical composition comprising AVE0010 and insulin glargine
US9085757B2 (en)	2010-06-17	2015-07-21	Regents Of The University Of Minnesota	Production of insulin producing cells
US8532933B2 (en)	2010-06-18	2013-09-10	Roche Diagnostics Operations, Inc.	Insulin optimization systems and testing methods with adjusted exit criterion accounting for system noise associated with biomarkers
EP2611458B1 (en)	2010-08-30	2016-09-21	Sanofi-Aventis Deutschland GmbH	Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
CN103167878A (en)	2010-10-27	2013-06-19	诺沃—诺迪斯克有限公司	Treating diabetes melitus using insulin injections administered with varying injection intervals
WO2012065996A1 (en)	2010-11-15	2012-05-24	Sanofi-Aventis Deutschland Gmbh	PHARMACEUTICAL FORMULATION COMPRISING INSULIN GLARGINE AND MALTOSYL-ß-CYCLODEXTRIN
WO2012066086A1 (en)	2010-11-17	2012-05-24	Sanofi-Aventis Deutschland Gmbh	PHARMACEUTICAL FORMULATION COMPRISING INSULIN GLARGINE AND SULFOBUTYL ETHER 7-ß-CYCLODEXTRIN
TW201236692A (en)	2011-02-02	2012-09-16	Sanofi Aventis Deutschland	Prevention of hypoglycaemia in diabetes mellitus type 2 patients
ES2733646T3 (en)	2011-03-11	2019-12-02	Beth Israel Deaconess Medical Ct Inc	Anti-CD40 antibodies and uses thereof
EP2763691A1 (en)	2011-10-04	2014-08-13	Sanofi-Aventis Deutschland GmbH	Glp-1 agonist for use in the treatment of stenosis or/and obstruction in the biliary tract

2011
- 2011-05-16 AU AU2011202239A patent/AU2011202239C1/en active Active
- 2011-05-17 EP EP18161680.6A patent/EP3424491A1/en not_active Withdrawn
- 2011-05-17 TR TR2018/09475T patent/TR201809475T4/en unknown
- 2011-05-17 TW TW100117134A patent/TWI469787B/en active
- 2011-05-17 EP EP11166415.7A patent/EP2387989B1/en active Active
- 2011-05-17 PT PT111664157T patent/PT2387989E/en unknown
- 2011-05-17 DK DK14166877.2T patent/DK2781212T3/en active
- 2011-05-17 UY UY0001033391A patent/UY33391A/en active IP Right Grant
- 2011-05-17 EP EP20199940.6A patent/EP3824876B8/en active Active
- 2011-05-17 RS RSP20140522 patent/RS53559B1/en unknown
- 2011-05-17 PL PL20199940.6T patent/PL3824876T3/en unknown
- 2011-05-17 ES ES11166415.7T patent/ES2509943T3/en active Active
- 2011-05-17 EP EP14166877.2A patent/EP2781212B1/en active Active
- 2011-05-17 HU HUE14166877A patent/HUE039355T2/en unknown
- 2011-05-17 DK DK11166415.7T patent/DK2387989T3/en active
- 2011-05-17 JO JO2011163A patent/JO2944B1/en active
- 2011-05-17 SI SI201131519T patent/SI2781212T1/en unknown
- 2011-05-17 EP EP23157670.3A patent/EP4218723A3/en not_active Withdrawn
- 2011-05-17 SI SI201130267T patent/SI2387989T1/en unknown
- 2011-05-17 AR ARP110101688A patent/AR081200A1/en not_active Application Discontinuation
- 2011-05-17 JP JP2011110037A patent/JP5269945B2/en active Active
- 2011-05-17 ES ES14166877.2T patent/ES2676401T3/en active Active
- 2011-05-17 PL PL14166877T patent/PL2781212T3/en unknown
- 2011-05-17 TW TW104116749A patent/TWI605825B/en active
- 2011-05-17 TW TW106106304A patent/TW201735941A/en unknown
- 2011-05-17 EP EP19184732.6A patent/EP3636250A1/en not_active Withdrawn
- 2011-05-17 ES ES20199940T patent/ES2945208T3/en active Active
- 2011-05-17 LT LTEP14166877.2T patent/LT2781212T/en unknown
- 2011-05-17 PT PT141668772T patent/PT2781212T/en unknown
- 2011-05-17 PL PL11166415T patent/PL2387989T3/en unknown
- 2011-05-17 TW TW103110412A patent/TWI496580B/en active
- 2011-05-18 HU HUE11720115A patent/HUE039354T2/en unknown
- 2011-05-18 SI SI201131518T patent/SI2571517T2/en unknown
- 2011-05-18 MX MX2012011278A patent/MX343489B/en active IP Right Grant
- 2011-05-18 KR KR1020187021814A patent/KR101989343B1/en active Active
- 2011-05-18 PH PH1/2012/501895A patent/PH12012501895A1/en unknown
- 2011-05-18 KR KR1020127026802A patent/KR101486743B1/en active Active
- 2011-05-18 BR BR112012029131-9A patent/BR112012029131B1/en active IP Right Grant
- 2011-05-18 PL PL11720115.2T patent/PL2571517T5/en unknown
- 2011-05-18 TR TR2018/09514T patent/TR201809514T4/en unknown
- 2011-05-18 PE PE2012002170A patent/PE20130511A1/en active IP Right Grant
- 2011-05-18 NZ NZ602541A patent/NZ602541A/en unknown
- 2011-05-18 SG SG10201510406YA patent/SG10201510406YA/en unknown
- 2011-05-18 MY MYPI2012004140A patent/MY156188A/en unknown
- 2011-05-18 EP EP18155758.8A patent/EP3400931A1/en not_active Withdrawn
- 2011-05-18 CA CA2792669A patent/CA2792669C/en active Active
- 2011-05-18 MX MX2019003693A patent/MX389052B/en unknown
- 2011-05-18 EP EP11720115.2A patent/EP2571517B9/en active Active
- 2011-05-18 KR KR1020177016698A patent/KR20170072960A/en not_active Ceased
- 2011-05-18 PE PE2016000735A patent/PE20160781A1/en unknown
- 2011-05-18 PT PT117201152T patent/PT2571517T/en unknown
- 2011-05-18 ES ES11720115T patent/ES2690302T5/en active Active
- 2011-05-18 MA MA35358A patent/MA34224B1/en unknown
- 2011-05-18 SG SG2012084208A patent/SG185593A1/en unknown
- 2011-05-18 US US13/110,568 patent/US20110301081A1/en not_active Abandoned
- 2011-05-18 HR HRP20181028TT patent/HRP20181028T2/en unknown
- 2011-05-18 DK DK11720115.2T patent/DK2571517T4/en active
- 2011-05-18 BR BR122019006884-4A patent/BR122019006884B1/en active IP Right Grant
- 2011-05-18 EP EP19174460.6A patent/EP3607935A1/en not_active Withdrawn
- 2011-05-18 LT LTEP11720115.2T patent/LT2571517T/en unknown
- 2011-05-18 WO PCT/EP2011/058079 patent/WO2011144673A2/en not_active Ceased
- 2011-05-18 KR KR1020147023925A patent/KR101913672B1/en active Active
- 2011-05-18 RU RU2011119988/15A patent/RU2564104C2/en active
- 2011-05-18 FI FIEP11720115.2T patent/FI2571517T4/en active
- 2011-05-19 CN CN201710324824.8A patent/CN107583038A/en active Pending
- 2011-05-19 CN CN201410818149.0A patent/CN104622788A/en active Pending
- 2011-05-19 CN CN201710249012.1A patent/CN107583037A/en active Pending
- 2011-05-19 CN CN2011102251176A patent/CN102319422A/en not_active Withdrawn
- 2011-05-19 CN CN201410220537.9A patent/CN103948913A/en active Pending
- 2011-12-02 US US13/310,118 patent/US20120122774A1/en not_active Abandoned
2012
- 2012-03-13 HK HK18108479.3A patent/HK1248593A1/en unknown
- 2012-03-13 HK HK15111312.1A patent/HK1210435A1/en unknown
- 2012-03-13 HK HK18108478.4A patent/HK1248592A1/en unknown
- 2012-03-13 HK HK14111946.6A patent/HK1198428A1/en unknown
- 2012-09-13 IL IL221964A patent/IL221964A/en active IP Right Grant
- 2012-09-18 ZA ZA2012/06998A patent/ZA201206998B/en unknown
- 2012-10-01 TN TNP2012000478A patent/TN2012000478A1/en unknown
- 2012-10-02 DO DO2012000261A patent/DOP2012000261A/en unknown
- 2012-10-03 NI NI201200152A patent/NI201200152A/en unknown
- 2012-10-23 GT GT201200287A patent/GT201200287A/en unknown
- 2012-11-08 CO CO12201607A patent/CO6640217A2/en unknown
- 2012-11-13 CR CR20120578A patent/CR20120578A/en unknown
- 2012-11-15 CL CL2012003197A patent/CL2012003197A1/en unknown
- 2012-11-16 EC ECSP12012298 patent/ECSP12012298A/en unknown
2013
- 2013-05-07 JP JP2013097274A patent/JP2013147509A/en not_active Withdrawn
2014
- 2014-03-20 US US14/220,562 patent/US9345750B2/en active Active
- 2014-09-11 HR HRP20140860AT patent/HRP20140860T1/en unknown
- 2014-10-15 CY CY20141100842T patent/CY1115649T1/en unknown
2015
- 2015-02-17 US US14/624,575 patent/US20150164999A1/en not_active Abandoned
- 2015-06-03 JP JP2015112917A patent/JP6333775B2/en active Active
- 2015-06-19 PH PH12015501421A patent/PH12015501421B1/en unknown
- 2015-08-06 RU RU2015132860A patent/RU2642662C2/en active
- 2015-10-07 JO JOP/2015/0245A patent/JOP20150245B1/en active
2016
- 2016-04-20 US US15/134,152 patent/US20160228516A1/en not_active Abandoned
- 2016-05-23 US US15/162,563 patent/US20160339084A1/en not_active Abandoned
2017
- 2017-03-21 IL IL251318A patent/IL251318B/en active IP Right Grant
- 2017-12-13 JP JP2017238185A patent/JP2018044003A/en active Pending
- 2017-12-27 RU RU2017146048A patent/RU2017146048A/en unknown
2018
- 2018-07-04 CY CY20181100701T patent/CY1120407T1/en unknown
- 2018-07-04 CY CY181100700T patent/CY1121042T1/en unknown
- 2018-07-04 HR HRP20181026TT patent/HRP20181026T1/en unknown
- 2018-08-21 US US16/108,064 patent/US20190046616A1/en not_active Abandoned
2019
- 2019-03-11 PH PH12019500517A patent/PH12019500517A1/en unknown
- 2019-03-28 US US16/368,201 patent/US20190388511A1/en not_active Abandoned
- 2019-09-17 US US16/572,850 patent/US20200215163A1/en not_active Abandoned
- 2019-12-13 JP JP2019224977A patent/JP2020040990A/en active Pending
2020
- 2020-05-13 US US15/930,643 patent/US20200384087A1/en not_active Abandoned
2021
- 2021-02-16 US US17/176,442 patent/US20210308225A1/en not_active Abandoned

Also Published As

Publication number	Publication date
PH12019500517A1 (en)	2020-03-02
LT2571517T (en)	2018-07-25
EP2571517B2 (en)	2024-06-19
PT2571517T (en)	2018-07-10
ES2690302T3 (en)	2018-11-20
EP2571517A2 (en)	2013-03-27
PL2571517T3 (en)	2018-09-28
US9345750B2 (en)	2016-05-24
EP4218723A2 (en)	2023-08-02
AR081200A1 (en)	2012-07-04
TWI469787B (en)	2015-01-21
KR101486743B1 (en)	2015-01-28
CN104622788A (en)	2015-05-20
JP2015172068A (en)	2015-10-01
US20190046616A1 (en)	2019-02-14
PT2781212T (en)	2018-07-10
RU2011119988A (en)	2012-11-27
NZ602541A (en)	2013-11-29
GT201200287A (en)	2015-03-09
TW201427684A (en)	2014-07-16
MX389052B (en)	2025-03-20
MX2019003693A (en)	2019-07-04
SI2781212T1 (en)	2018-08-31
HRP20181028T2 (en)	2025-01-03
KR101989343B1 (en)	2019-06-14
HK1248592A1 (en)	2018-10-19
JO2944B1 (en)	2016-03-15
IL251318A0 (en)	2017-05-29
CY1121042T1 (en)	2019-12-11
SI2387989T1 (en)	2014-10-30
JP2018044003A (en)	2018-03-22
NI201200152A (en)	2013-01-24
CL2012003197A1 (en)	2013-01-25
CN107583038A (en)	2018-01-16
PL2781212T3 (en)	2018-08-31
CN107583037A (en)	2018-01-16
PL3824876T3 (en)	2024-02-19
US20160339084A1 (en)	2016-11-24
EP3607935A1 (en)	2020-02-12
RU2017146048A3 (en)	2021-07-01
RU2017146048A (en)	2019-06-27
EP3424491A1 (en)	2019-01-09
US20120122774A1 (en)	2012-05-17
ES2945208T3 (en)	2023-06-29
US20190388511A1 (en)	2019-12-26
CA2792669C (en)	2015-09-29
KR101913672B1 (en)	2018-11-01
HK1210435A1 (en)	2016-04-22
KR20180088752A (en)	2018-08-06
TR201809475T4 (en)	2018-07-23
EP2387989B1 (en)	2014-07-16
PL2571517T5 (en)	2024-12-02
PH12012501895A1 (en)	2016-02-03
TW201208695A (en)	2012-03-01
PH12015501421A1 (en)	2015-09-07
EP2781212B1 (en)	2018-04-04
UY33391A (en)	2011-10-31
ES2676401T3 (en)	2018-07-19
SI2571517T1 (en)	2018-08-31
MX2012011278A (en)	2012-11-06
EP2571517B9 (en)	2024-10-16
JP2013147509A (en)	2013-08-01
CN102319422A (en)	2012-01-18
PE20160781A1 (en)	2016-08-26
HRP20181028T1 (en)	2018-08-24
CN103948913A (en)	2014-07-30
TW201607552A (en)	2016-03-01
ZA201206998B (en)	2013-05-29
SI2571517T2 (en)	2024-10-30
IL251318B (en)	2018-12-31
FI2571517T4 (en)	2024-09-20
HUE039355T2 (en)	2018-12-28
PH12015501421B1 (en)	2015-09-07
WO2011144673A3 (en)	2012-05-03
AU2011202239B2 (en)	2012-06-07
AU2011202239C1 (en)	2017-03-16
KR20170072960A (en)	2017-06-27
EP3824876B1 (en)	2023-02-22
HUE039354T2 (en)	2018-12-28
US20110301081A1 (en)	2011-12-08
JP2020040990A (en)	2020-03-19
JOP20150245B1 (en)	2021-08-17
DK2571517T4 (en)	2024-09-23
AU2011202239A1 (en)	2011-12-08
DK2781212T3 (en)	2018-07-23
EP2387989A2 (en)	2011-11-23
US20210308225A1 (en)	2021-10-07
EP4218723A3 (en)	2023-11-08
HK1198428A1 (en)	2015-04-24
PT2387989E (en)	2014-09-15
BR122019006884B1 (en)	2022-08-23
PE20130511A1 (en)	2013-05-02
CO6640217A2 (en)	2013-03-22
DK2387989T3 (en)	2014-10-20
EP3824876A1 (en)	2021-05-26
CR20120578A (en)	2013-03-04
ES2690302T5 (en)	2024-12-03
WO2011144673A2 (en)	2011-11-24
ECSP12012298A (en)	2012-12-28
RU2642662C2 (en)	2018-01-25
SG185593A1 (en)	2012-12-28
ES2690302T9 (en)	2025-01-02
TWI605825B (en)	2017-11-21
HRP20181026T1 (en)	2018-08-24
RU2015132860A (en)	2017-02-09
CY1115649T1 (en)	2017-01-04
MY156188A (en)	2016-01-29
HK1248593A1 (en)	2018-10-19
EP2387989A3 (en)	2012-04-18
PL2387989T3 (en)	2014-12-31
TN2012000478A1 (en)	2014-04-01
US20200384087A1 (en)	2020-12-10
CY1120407T1 (en)	2019-07-10
ES2509943T3 (en)	2014-10-20
BR112012029131B1 (en)	2020-03-10
EP3824876B8 (en)	2023-08-02
TW201735941A (en)	2017-10-16
JP5269945B2 (en)	2013-08-21
JP2011241213A (en)	2011-12-01
US20150164999A1 (en)	2015-06-18
US20160228516A1 (en)	2016-08-11
KR20140109515A (en)	2014-09-15
KR20130040824A (en)	2013-04-24
HRP20140860T1 (en)	2014-10-24
DOP2012000261A (en)	2013-01-31
TWI496580B (en)	2015-08-21
BR112012029131A2 (en)	2016-09-13
US20140206611A1 (en)	2014-07-24
RS53559B1 (en)	2015-02-27
EP3636250A1 (en)	2020-04-15
MX343489B (en)	2016-11-08
DK2571517T3 (en)	2018-07-23
RU2564104C2 (en)	2015-09-27
LT2781212T (en)	2018-07-25
JP6333775B2 (en)	2018-05-30
EP3400931A1 (en)	2018-11-14
HRP20181028T4 (en)	2024-09-27
CA2792669A1 (en)	2011-11-24
MA34224B1 (en)	2013-05-02
HK1202428A1 (en)	2015-10-02
EP2781212A1 (en)	2014-09-24
TR201809514T4 (en)	2018-07-23
EP2571517B1 (en)	2018-04-04
US20200215163A1 (en)	2020-07-09
IL221964A (en)	2017-04-30

Publication	Publication Date	Title
IL251318B (en)	2018-12-31	Long-acting formulations of insulins
PT2866825T (en)	2020-07-15	Use of long-acting glp-1 peptides
IL223206A0 (en)	2013-02-03	Vaccine formulations
SI2603232T1 (en)	2020-03-31	Stable formulations of linaclotide
EP2552210A4 (en)	2014-01-15	Formulations of mazindol
PL2407155T3 (en)	2013-05-31	Formulations of inecalcitol
ZA201205646B (en)	2013-04-24	Spiroindoline compounds for use as anthelminthics
AP2013006687A0 (en)	2013-01-31	Formulations
PT3824876T (en)	2023-05-18	Long-acting formulations of insulins
GB201005587D0 (en)	2010-05-19	Novel formulations
TWM400763U (en)	2011-04-01	Improved structure of cold-accumulating cravats
TWM388315U (en)	2010-09-11	Improved structure of hemoclip
HU1000688D0 (en)	2011-02-28	Use of trifluoro-phal